Medicine
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
The new perioperative regimen cuts death risk by 42% in cisplatin-ineligible patients, marking a major expansion for AstraZeneca’s oncology portfolio.
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
Discover the preliminary clinical evidence thresholds cell therapies must achieve to secure simultaneous FDA RMAT and Fast Track designations.
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
Following successful Phase 3 trial results, mRNA platforms are emerging as a versatile, rapid tool for training the immune system to target…
-
How the OncoMate MSI Dx Test Guides Pembrolizumab Therapy
Discover how the OncoMate MSI Dx test uses PCR technology to identify MSI-H solid tumors and match patients with pembrolizumab immunotherapy.
-
Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial
A new study shows that adding an experimental drug to standard chemotherapy significantly improves survival outcomes for patients with metastatic pancreatic cancer.
-
UCSF Scientists Eliminate Deadly Brain Tumors in Mice with B-SYNC Therapy
Engineered B-SYNC CAR-T cells successfully wiped out diffuse midline glioma in mice, paving the way for human clinical trials as early as…
-
Understanding Metastatic Prostate Cancer Prognosis and Modern Treatment Pathways
As Joe Biden scales back public appearances due to metastatic prostate cancer, we examine the clinical realities of high-risk disease and current…
-
Nangibotide Targets Acute-on-Chronic Liver Failure With Phase 2 Data Due 2027
Genfit advances TREM-1 modulator into ACLF after prior Phase 2 trials showed safety signals in septic shock and severe COVID-19.
-
Lenacapavir PrEP Costs $42,250 a Year in the U.S. Versus $60 for Generic Pills
The twice-yearly injection keeps 86% of users adherent versus 46% for daily pills, but the wholesale price gap exceeds $42,000 annually for…
-
Study Finds Autistic Adults Over 45 Face Nearly Triple Parkinsonism Rates
A U.S. Medicare analysis shows Parkinsonism prevalence of 3.8% in autistic seniors versus 1.6% in peers, highlighting new neurodegenerative risks for the…
-
Overcoming Immunotherapy Resistance Takes Center Stage at SITC 2026
Researchers at the SITC annual meeting tackle major cancer immunotherapy challenges, from metabolic resistance mechanisms to novel combination trials.
-
How Amivantamab’s Dual EGFR-MET Blockade Overcomes Resistance in Head and Neck Cancer
The first new drug in a decade for advanced HNSCC uses a bispecific antibody to hit two escape pathways at once, doubling…
-
START Opens First Italian Early-Phase Cancer Trial Site in Rome
Strategic partnership establishes first START site in Italy, expanding early-phase cancer trial access to patients in Rome and the Lazio region despite…
-
Personalized TMS Shows Promise for Severe OCD in Singapore Study
NUH and NUS Medicine report early success using fMRI-guided stimulation for treatment-resistant OCD, aiming to extend the method to depression and anxiety.
-
Inovio’s First FDA Approval Tests Whether DNA Medicines Can Pay Off for Retail Investors
Voceryq’s accelerated approval for a rare throat disease gives the Plymouth Meeting biotech its first product revenue, but confirmatory trials and a…
-
Study Links Louisiana Industrial Pollution to Fourfold Rise in Infant Heart Defects
New research finds babies born in high-pollution areas of southeast Louisiana face significantly higher odds of severe congenital heart defects.
-
Penn study finds patient navigators overcome hidden asthma barriers
A new trial shows trained navigators help low-income adults manage environmental and social obstacles, improving asthma control.
-
Personal Factors Driving Cancer Biomarker Decisions and Patient Outcomes
Gosselaar’s campaign highlights how personal health history and financial access shape biomarker testing choices and treatment precision.
-
Generic HIV Shot Cuts Cost to $40, Unlocking Access in 120 Low-Income Countries
FDA approval of Dr. Reddy’s lenacapavir generic enables affordable, twice-yearly HIV prevention for millions in developing regions.
-
Ractigen Launches Phase II Trial for Bladder Cancer Treatment
Ractigen Therapeutics initiates Phase II clinical trial for saRNA therapy RAG-01 to treat non-muscle invasive bladder cancer in China.
-
October FDA Approvals Beyond Cancer: Hives, Schizophrenia, Eye Disease, Hepatitis B and Crohn Disease
From allergy to ophthalmology, new October treatments bring first-in-class options and at-home therapies for chronic conditions and rare diseases.
-
Dendritic Cell Cancer Vaccines: One FDA Approval, Most Others Still in Trials
Only sipuleucel-T is approved for advanced prostate cancer; private clinics like Immunocine in Mexico sell personalized dendritic cell therapies still in clinical…
-
How New Immunotherapy Aims to Break the Cycle of Surgery for RRP Patients
The FDA has approved VOCERYQ, a novel DNA-based immunotherapy designed to reduce the need for repeated surgical interventions in adults with RRP.
-
BioSapien Begins First-in-Human MediChip Trial for Rectal Cancer at Burjeel
Abu Dhabi startup BioSapien doses first patient in Phase I trial evaluating its biodegradable MediChip implant to deliver localized chemotherapy directly to…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992